PRENOVA® is the latest patented
and most advanced solution for
Rapid High Sensitivity Testing in the industry.
Innovating in Rapid High Sensitivity Testing
We are actively involved in developing new technologies, as well as constantly reviewing and updating our own technologies.
With our focus and mindset, we aim to meet customers rapidly changing needs.
Advancing Rapid High Sensitivity Testing with the potential to protect lives.
COVID-19, PRENOVA®COV1
At the dawn of the COVID19 pandemic our specific know-how and patented technology platform has been implemented in finding a solution to decrease the sterility testing time for the COVID19 vaccine to increase global safety. With a just-in-time strategy PRENOVA® COV1 was developed to help and validate sterility and administer vaccines as soon as possible. With our PRENOVA® platform we have made the most advanced discovery in our industry which can be implemented to reduce the go-to-market time for a gamma of vaccines.
The race for vaccine development has the pharma and biotech conglomerates requesting for a rapid and precise testing method.
The PRENOVA®COV1 platform is such a microbial detection system including instrument, reagents, software and customized support.
At the core of PRENOVA®COV1 is the proprietary and patented ATP testing method accepted globally due to reliability. Current methods require a 14-days sterility test waiting time before it can be released to the general public. PRENOVA®COV1 takes approximately 48 hours to respond, reducing the go-to-market time dramatically.
We are prepared for mass production and global demand from manufacturers and governments.
We are ready, today.
PRENOVA®TCT3, FOCUS ON A HOLISTIC PATIENT CENTRICITY
We have kept a holistic focus on the patient who is fighting various forms of cancer while developing the PRENOVA® platform. By giving back TIME there are less chances on infections and other complications due to reduced/non-active immune system. Sterility (QCrelease) testing is an important part in the release of medication to patients. PRENOVA®TCT3 is engineered especially for this purpose.
PRENOVA® FOR CAR-T
Today CAR–T therapies typically represent the final treatment option for patients suffering from various forms of cancer. It is critical that CAR–T therapies are manufactured and returned to the patient in an expedited manner. As such, manufacturers of CAR–T therapies must adopt and utilize Quality Risk Management (QRM) principles during manufacture, testing, and release.
Based on a well-defined and documented microbial contamination control strategy, it should be possible for manufacturers to implement a just-in-time microbiological release strategy.
PRENOVA®TCT3
PRENOVA® TCT3 enables you to differentiate human from microbial ATP.
Our patented proprietary technology makes it possible to significantly shorten the test release time to 2-3 days for T-cell therapies.
The need for rapid testing of microbial loads in human matrixes has exponentially grown since the success of CAR-T therapies in the treatment of advanced or aggressive forms of cancer.
Patients have a disrupted immune system due to treatments and the cancer itself where a just-in-time microbiology release strategy is implemented to eliminate the risk of microbial contamination to administer the CAR-T therapy as soon as possible. This is exactly the reason why we have developed our PRENOVA® TCT3 RAPID TEST where we can give back precious time.
PRENOVA® TCT3 has a significant shorter test lead time of 48-72 hours (2-3 days) with a smaller required test volume for detection of the total microbial load.
The PRENOVA® TCT3 rapid test consists of the assay (reagents) and the reader. The NOVILITE reader is a luminometer specifically engineered for the sensitivity of the kinetic measurement of the PRENOVA® TCT3 assay.
Partners
PRENOVA® partners are located worldwide.
Contact us
We are always happy to hear from you, we want to listen to your requirements and offer the best solution
If you want to talk directly to one of our experts, please do not hesitate to call us +31 46 458 6776
-
HQ
De Asselen Kuil 12 6161 RD Geleen
The Netherlands
-
Tech Center
Hofdwarsweg 45
6161 DE Geleen
The Netherlands